GRIPHON Trial—Designed With a Composite Primary Endpoint to Assess the Effect of UPTRAVI® (selexipag) on Long-term Disease Progression1

GRIPHON Trial Primary Endpoint Image

Primary endpoint is consistent with the recommendations of the 5th World Symposium on Pulmonary Hypertension2

*All events adjudicated by a blinded critical event committee.3